Search clinical trials for: immunological answer

Total 13782 results

EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Not yet recruiting

Study of Avelumab and Tuvusertib in Participants With Advanced Urothelial Cancer That Has Progressed on Prior Anti-PD-(L)1 Therapy (JAVELIN DDRiver Bladder)

Urothelial Carcinoma

United States, Germany
BeiGene

Not yet recruiting

Phase 1 First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors

Advanced Solid Tumor
National Cancer Institute (NCI)

Recruiting

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 | Metastatic Undifferentiated Pleomorphic Sarcoma | Unresectable Undifferentiated Pleomorphic Sarcoma | Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8

United States
Chen Xiaoping

Not yet recruiting

Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning Model

HCC
Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NSCLC | Non-small Cell Lung Cancer

Israel, United States
Peking University Third Hospital
Biotech Pharmaceutical Co., Ltd.

Not yet recruiting

SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer (Nim-PC-28)

Advanced Pancreatic Cancer
Peking University Cancer Hospital & Institute

Recruiting

RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression

Fallopian Tube Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma

China
Marmara University

Recruiting

Immunological Parameters Between MRONJ Stages

Medication-Related Osteonecrosis of Jaw

Turkey
Melanoma and Skin Cancer Trials Limited

Not yet recruiting

Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma (NEOPECS)

Locally Advanced Cutaneous Squamous Cell Carcinoma
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer
University of Kansas Medical Center

Not yet recruiting

Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients

Solid Tumor

United States
Peter MacCallum Cancer Centre, Australia
AbbVie

Not yet recruiting

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)

Relapsed/Refractory Large B-cell Lymphoma

Australia
Acepodia Biotech, Inc.

Not yet recruiting

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Metastatic Solid Tumor | Locally Advanced Solid Tumor

United States
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (DUPLE)

Pulmonary Large-cell Neuroendocrine Carcinoma

Italy
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Advanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer
National Cancer Center, China

Not yet recruiting

Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation

NSCLC
Zhangfa Song

Not yet recruiting

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

Metastatic Colorectal Cancer | MSS

China
Institute of Hematology & Blood Diseases Hospital...

Recruiting

Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma

B Cell Lymphoma

China
Osel, Inc.
City of Hope Comprehensive Cancer Center; Miyarisan Pharmaceutical Co., Ltd.

Recruiting

Dose Finding Study of CBM588 in Combination With Nivolumab/Ipilimumab in Advanced Stage Renal Cell Carcinoma

Advanced or Metastatic Renal Cell Carcinoma

United States
Tianjin Medical University Cancer Institute and...

Recruiting

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

HCC

China
M.D. Anderson Cancer Center

Not yet recruiting

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Metastatic Colorectal Cancer | KRAS G12C Mutations

United States
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...

Recruiting

JAVEMACS: Japan AVElumab Maintenance And Continuous Treatment Study

Urothelial Carcinoma

Japan
Masonic Cancer Center, University of Minnesota

Recruiting

MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

Acquired Pure Red Cell Aplasia | Paroxysmal Nocturnal Hemoglobinuria | Severe Aplastic Anemia | Acquired Amegakaryocytic Thrombocytopenia

United States
Peking Union Medical College Hospital
Shengjing Hospital; The Affiliated Hospital of Qingdao University; Children's... and other collaborators

Recruiting

Belimumab After Rituximab in Resistant Primary Juvenile SS (BRRPJS)

Pediatric ALL | Sjogren's Syndrome

China
xiaohua li

Not yet recruiting

Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

Gastroesophageal Junction Cancer
National Cancer Institute (NCI)

Not yet recruiting

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Colorectal Cancer | Gastroesophageal Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Cancer | Chemotherapy | Immunotherapy | Chemoradiotherapy | Nimotuzumab

China
Vall d'Hebron Institute of Oncology

Not yet recruiting

Combination Therapy for BRAF-V600E Metastatic CRCm (BRAVE)

Metastatic Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

Liver Cancer
University Hospital, Basel, Switzerland

Not yet recruiting

Safety and Modulation of Adaptive Immunity by Iscador® Qu Viscum Album Extract in Patients With Advanced, Recurrent or Metastatic Cancers Treated With Immune Checkpoint Inhibitors (ISCA-CHECK)

Advanced Solid Tumor

Switzerland
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Metastatic Breast Cancer

United States
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Pancreatic Cancer

China
Stanford University

Recruiting

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

Leukemia | Acute Lymphoblastic Leukemia

United States
Tel Aviv Medical Center

Not yet recruiting

Neoadjuvant Pembrolizumab, Carboplatin and Paclitaxel in Triple-negative Breast Cancer

Triple Negative Breast Cancer
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Tianjin Medical University Cancer Institute and...

Recruiting

Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study

Pancreatic Cancer

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Prospective, Single-arm, Multicenter Phase II Clinical Study of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma | Adebrelimab

China
Tianjin Medical University Cancer Institute and...

Recruiting

Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis

Pancreatic Cancer

China
CDR-Life AG

Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

Select Advanced Solid Tumors

United States, Denmark
Maastricht University Medical Center
Gilead Sciences

Not yet recruiting

Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases

NSCLC Stage IV | Brain Metastases, Adult

Netherlands
Twinpig Biolab, Inc.

Not yet recruiting

Clinical Trial of TB511 in Advanced Solid Tumors

Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Prostate Cancer
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
Osel, Inc.
National Cancer Institute (NCI); City of Hope Medical Center; Miyarisan Pharmaceuticals...

Recruiting

CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer

Metastatic Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Sarcomatoid Renal Cell Carcinoma | Advanced Renal Cell Carcinoma | Advanced Sarcomatoid Renal...

United States
Fujian Cancer Hospital

Not yet recruiting

The Efficacy and Safety of Tislelizumab Combined With Anlotinib and S1 Plus Oxaliplatin as Neoadjuvant Therapy for the Locally Advanced Adenocarcinoma of Esophagogastric Junction

Immunotherapy Gastroesophageal Junction

China
Chinese PLA General Hospital

Recruiting

Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma

China
Zhejiang Cancer Hospital

Recruiting

Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer

Non-Resectable Pancreas Carcinoma

China
Merck Sharp & Dohme LLC

Not yet recruiting

A Study of Pembrolizumab in Combination With Investigational Agents in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01B/LIGHTBEAM-U01)

Neoplasm Metastasis
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions

Search clinical trials for: immunological answer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations